Results 1-20 of 81 for vaccine speaker:Clare Daly

HPV Vaccine: Motion [Private Members] (28 Mar 2018)

Clare Daly: I move amendment No. 1:(a) To insert the following words after "decade;":“— a number of individuals who have received the vaccine have experienced severe health problems in the time period after receiving the vaccine;" and(b) To insert the following words after "secondary school; and":"calls on the Government to: — instruct the HSE to engage with those who have...

Written Answers — Department of Health: Vaccination Programme (21 Jul 2016)

Clare Daly: 435. To ask the Minister for Health the likely date upon which the Health Service Executive will restock with the BCG vaccine; the likely date for the recommencement of the BCG vaccination programme; and his views in regard to the current suspension of this vaccination programme [23421/16]

Written Answers — Department of Health: Vaccination Programme (15 Nov 2016)

Clare Daly: 491. To ask the Minister for Health the data that the manufacturer submitted to the EMA which indicated that those pre-exposed to vaccine relevant HPV may experience a 44.6% increased risk of pre-cancerous lesions after vaccination with Gardasil; and the steps in place to monitor cervical cancer rates in the HPV vaccinated population. [34598/16]

Written Answers — Department of Health: Vaccination Programme Data (2 May 2017)

Clare Daly: 872. To ask the Minister for Health the cost of the swine flu vaccination programme; and the cost of the vaccines purchased, the public mass vaccination campaign, the setting up of emergency clinics around the country, the extra staff costs in hiring part time staff and for overtime, the media campaign and other associated costs. [19464/17]

Written Answers — Department of Health: Vaccination Programme Data (2 May 2017)

Clare Daly: 868. To ask the Minister for Health further to Parliamentary Questions Nos. 609 to 611 of 11 April 2017, the reason he has stated that there was more vaccine produced by a company (details supplied) purchased than that of another company; and the reason 90% of the swine flu vaccinations were of the pandemrix vaccine as distinct from cephlapan. [19460/17]

Written Answers — Department of Health: Vaccination Programme Data (26 Jun 2018)

Clare Daly: 361. To ask the Minister for Health the number of doses of the HPV vaccine administered here to date; and the number of cases of anaphylactic or anaphylactoid reactions reported to the HPRA within the first three years of the vaccine being administered through the school system, that is between 1 September 2010 and 1 June 2013, before the number of vaccine doses per patient was reduced from...

Written Answers — Department of Health: Vaccination Programme (26 Feb 2019)

Clare Daly: 399. To ask the Minister for Health the way in which the Health Products Regulatory Authority plans to monitor the safety of the HPV vaccine Gardasil 9 as a black triangle product; if it is to be administered to girls and boys here simultaneously with other vaccines as proposed by HIQA in its health technology assessment on extending the HPV vaccination to boys; and if he will make a...

Written Answers — Department of Health: Vaccination Programme (15 Nov 2016)

Clare Daly: 487. To ask the Minister for Health if he will consider that parents and guardians should be given the option of providing consent for each HPV vaccination and not as it is at present, that is, consenting for at the start of the series of jabs; if he will consider providing the parents the right to give consent individually for the two vaccinations; and his views on the fact that this...

Written Answers — Department of Health: Vaccination Programme (21 Jul 2016)

Clare Daly: 436. To ask the Minister for Health when the meningitis B vaccination programme for children will commence given that such a vaccination programme is a recommendation of the national immunisation advisory committee. [23422/16]

Written Answers — Department of Health: Vaccination Programme (23 Mar 2017)

Clare Daly: 152. To ask the Minister for Health if his attention has been drawn to the content of an anti-vaccine propaganda film (details supplied); and the steps his Department will take to counter any inaccurate information regarding vaccinations that feature in this film. [14689/17]

Written Answers — Department of Health: Vaccination Programme Data (11 Apr 2017)

Clare Daly: 610. To ask the Minister for Health the number of doses of pandemrix which were purchased; the number of doses which were used during the swine flu vaccination programme; the position regarding the remainder of those unused vaccines; and if he will make a statement on the matter. [18168/17]

Written Answers — Department of Health: Vaccination Programme (23 May 2017)

Clare Daly: 444. To ask the Minister for Health if he will establish an expert medical group on the HPV vaccination along the lines of the previous group established in November 1977 on the whooping cough vaccination. [24144/17]

Written Answers — Department of Health: Vaccination Programme (10 May 2018)

Clare Daly: 173. To ask the Minister for Health if the urgent introduction of a no-fault vaccine payment scheme for persons debilitated by narcolepsy as a result of being vaccinated with the drug Pandemrix will be considered; and if he will make a statement on the matter. [20525/18]

Written Answers — Department of Health: Vaccination Programme (13 Nov 2018)

Clare Daly: 379. To ask the Minister for Health to identify the person who authorised the HSE not to include the vaccine manufacturers package leaflets in school packs instead substituting these leaflets with the HSE vaccine information leaflets and booklets. [46831/18]

Written Answers — Department of Health: Vaccine Damage Compensation Scheme (8 May 2019)

Clare Daly: 921. To ask the Minister for Health the level of liability of the pharmaceutical industry in respect of vaccine injury; and if it has been indemnified by the State with the Exchequer taking on liability such as in the Pandemrix vaccination programme. [19548/19]

Written Answers — Department of Health: Vaccination Programme (15 Nov 2016)

Clare Daly: 490. To ask the Minister for Health if pandemrix was at one time considered as safe as the HPV vaccines and that the benefits outweighed the risks; and if there is a possibility that the many autoimmune reactions being experienced by HPV vaccinated girls are following a similar pattern of neurological disturbances. [34597/16]

Written Answers — Department of Health: Vaccine Damage Compensation Scheme (15 May 2018)

Clare Daly: 394. To ask the Minister for Health to outline the consideration he has given to the request from a group (details supplied) to have an inquiry into the vaccine reactions, subsequent injury and early death of some children that received the DPT vaccine; and if he will make a statement on the matter. [21010/18]

Written Answers — Department of Health: Vaccination Programme (30 May 2018)

Clare Daly: 140. To ask the Minister for Health the reason the HSE failed to provide parents with the HPV vaccine Gardasil manufacturer's package leaflet in the HSE parent information packs which promote the vaccine, particularly in view of the disclaimer contained on the HSE's website; and if he will make a statement on the matter. [23838/18]

Written Answers — Department of Health: HIV-AIDS Programmes (13 Jun 2018)

Clare Daly: 123. To ask the Minister for Health his views on the HSE promotional campaign for the HPV vaccine which contains captions such as armed for life and protect our future and states that the HPV vaccine protects girls from getting cervical cancer when they are older in view of information (details supplied); and if he will make a statement on the matter. [25808/18]

Written Answers — Department of Health: Vaccination Programme (3 May 2017)

Clare Daly: 21. To ask the Minister for Health if he will provide the detail of the information held by his Department after November 2009 regarding the safety profile of the Pandemrix vaccine compared to other vaccines for swine flu; and if his Department was briefed by the Irish Medicines Board as to the heightened risk of serious adverse drug reactions associated with the drug. [20206/17]